Private equity investor Nordic Capital has acquired speciality pharmaceutical company Advanz Pharma in a deal worth $846 million (£596m).
The deal is expected to bring significant investment and expertise to help fuel Advanz Pharma’s growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to critical medicines globally.
Calling the acquisition “fantastic news for Advanz Pharma” CEO Graeme Duncan said it will help the company’s goal “of becoming the go-to partner for complex medicines in Europe”. “This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply.”
